vs
Side-by-side financial comparison of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and OneStream, Inc. (OS). Click either name above to swap in a different company.
OneStream, Inc. is the larger business by last-quarter revenue ($163.7M vs $86.8M, roughly 1.9× IOVANCE BIOTHERAPEUTICS, INC.). On growth, OneStream, Inc. posted the faster year-over-year revenue change (23.6% vs 17.7%). OneStream, Inc. produced more free cash flow last quarter ($25.6M vs $-61.9M). Over the past eight quarters, IOVANCE BIOTHERAPEUTICS, INC.'s revenue compounded faster (1001.6% CAGR vs 21.8%).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
Blue Stream provides cable television, cable telephone, DVR, and up to 1 GIG Internet speed broadband services to customers in the Florida communities of Coral Springs and Weston.
IOVA vs OS — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $86.8M | $163.7M |
| Net Profit | — | $999.0K |
| Gross Margin | 67.4% | 69.8% |
| Operating Margin | -84.7% | -3.2% |
| Net Margin | — | 0.6% |
| Revenue YoY | 17.7% | 23.6% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $86.8M | $163.7M | ||
| Q3 25 | $67.5M | $154.3M | ||
| Q2 25 | $60.0M | $147.6M | ||
| Q1 25 | $49.3M | $136.3M | ||
| Q4 24 | $73.7M | $132.5M | ||
| Q3 24 | $58.6M | $129.1M | ||
| Q2 24 | $31.1M | $117.5M | ||
| Q1 24 | $715.0K | $110.3M |
| Q4 25 | — | $999.0K | ||
| Q3 25 | $-91.3M | $-8.8M | ||
| Q2 25 | $-111.7M | $-18.4M | ||
| Q1 25 | $-116.2M | $-24.0M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-83.5M | $-171.9M | ||
| Q2 24 | $-97.1M | $-7.8M | ||
| Q1 24 | $-113.0M | $-5.0M |
| Q4 25 | 67.4% | 69.8% | ||
| Q3 25 | 43.0% | 68.1% | ||
| Q2 25 | 5.5% | 68.6% | ||
| Q1 25 | -0.8% | 68.0% | ||
| Q4 24 | 68.7% | 66.8% | ||
| Q3 24 | 46.2% | 50.1% | ||
| Q2 24 | -0.8% | 68.5% | ||
| Q1 24 | — | 69.1% |
| Q4 25 | -84.7% | -3.2% | ||
| Q3 25 | -140.7% | -11.3% | ||
| Q2 25 | -189.8% | -21.8% | ||
| Q1 25 | -245.8% | -29.3% | ||
| Q4 24 | -117.5% | -35.8% | ||
| Q3 24 | -152.1% | -197.6% | ||
| Q2 24 | -327.6% | -9.8% | ||
| Q1 24 | -16464.6% | -4.9% |
| Q4 25 | — | 0.6% | ||
| Q3 25 | -135.3% | -5.7% | ||
| Q2 25 | -186.2% | -12.5% | ||
| Q1 25 | -235.5% | -17.6% | ||
| Q4 24 | — | — | ||
| Q3 24 | -142.7% | -133.1% | ||
| Q2 24 | -312.2% | -6.7% | ||
| Q1 24 | -15800.8% | -4.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-0.28 | $-1.06 | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.42 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $297.0M | $693.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $698.6M | $504.7M |
| Total Assets | $913.2M | $1.0B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $297.0M | $693.6M | ||
| Q3 25 | $300.8M | $653.9M | ||
| Q2 25 | $301.2M | $652.1M | ||
| Q1 25 | $359.7M | $593.9M | ||
| Q4 24 | $323.8M | $544.2M | ||
| Q3 24 | $397.5M | $495.5M | ||
| Q2 24 | $412.5M | $140.5M | ||
| Q1 24 | $356.2M | — |
| Q4 25 | $698.6M | $504.7M | ||
| Q3 25 | $702.3M | $472.1M | ||
| Q2 25 | $698.5M | $458.2M | ||
| Q1 25 | $767.9M | $412.9M | ||
| Q4 24 | $710.4M | $386.2M | ||
| Q3 24 | $773.5M | $458.2M | ||
| Q2 24 | $768.5M | $97.5M | ||
| Q1 24 | $680.0M | $102.5M |
| Q4 25 | $913.2M | $1.0B | ||
| Q3 25 | $904.9M | $949.4M | ||
| Q2 25 | $907.4M | $910.5M | ||
| Q1 25 | $966.7M | $867.3M | ||
| Q4 24 | $910.4M | $823.2M | ||
| Q3 24 | $991.1M | $750.1M | ||
| Q2 24 | $964.3M | $379.7M | ||
| Q1 24 | $869.8M | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-52.6M | $25.8M |
| Free Cash FlowOCF − Capex | $-61.9M | $25.6M |
| FCF MarginFCF / Revenue | -71.3% | 15.7% |
| Capex IntensityCapex / Revenue | 10.7% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 25.79× |
| TTM Free Cash FlowTrailing 4 quarters | $-336.2M | $95.6M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-52.6M | $25.8M | ||
| Q3 25 | $-78.7M | $5.0M | ||
| Q2 25 | $-67.4M | $29.7M | ||
| Q1 25 | $-103.7M | $36.2M | ||
| Q4 24 | $-73.3M | — | ||
| Q3 24 | $-59.0M | $2.4M | ||
| Q2 24 | $-98.4M | $8.1M | ||
| Q1 24 | $-122.3M | $25.5M |
| Q4 25 | $-61.9M | $25.6M | ||
| Q3 25 | $-89.5M | $4.8M | ||
| Q2 25 | $-74.9M | $29.4M | ||
| Q1 25 | $-109.9M | $35.8M | ||
| Q4 24 | $-77.5M | — | ||
| Q3 24 | $-61.3M | $1.3M | ||
| Q2 24 | $-98.9M | $7.7M | ||
| Q1 24 | $-126.5M | $24.9M |
| Q4 25 | -71.3% | 15.7% | ||
| Q3 25 | -132.7% | 3.1% | ||
| Q2 25 | -124.9% | 19.9% | ||
| Q1 25 | -222.8% | 26.3% | ||
| Q4 24 | -105.1% | — | ||
| Q3 24 | -104.6% | 1.0% | ||
| Q2 24 | -317.9% | 6.6% | ||
| Q1 24 | -17685.3% | 22.5% |
| Q4 25 | 10.7% | 0.1% | ||
| Q3 25 | 16.1% | 0.1% | ||
| Q2 25 | 12.4% | 0.2% | ||
| Q1 25 | 12.6% | 0.3% | ||
| Q4 24 | 5.7% | — | ||
| Q3 24 | 3.9% | 0.8% | ||
| Q2 24 | 1.4% | 0.3% | ||
| Q1 24 | 583.4% | 0.6% |
| Q4 25 | — | 25.79× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
OS
| Subscription And Circulation | $150.3M | 92% |
| Professional Services And Other | $9.4M | 6% |
| License | $4.0M | 2% |
